Company profile: ViroPharma
1.1 - Company Overview
Company description
- Provider of biopharmaceutical products addressing serious diseases, focused on therapies used by physician specialists or in hospital settings; develops and commercializes treatments, with two marketed products and three development programs, including Vancocin HCl capsules.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ViroPharma
Biosplice
HQ: United States
Website
- Description: Provider of therapeutic solutions and clinical trials for tissue-level regeneration, developing therapies that modulate alternative splicing via CLK/DYRK kinase inhibition to treat diseases like osteoarthritis and cancer. Offerings include Lorecivivint, an injectable small molecule for knee osteoarthritis to reduce pain, improve function, and protect cartilage, with trials evaluating safety, efficacy, and dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biosplice company profile →
Oxford Biomedica
HQ: United Kingdom
Website
- Description: Provider of gene and cell therapy solutions, offering lentiviral LentiVector and AAV platforms for development and manufacturing of gene therapies, plus CDMO services for viral vectors including tech transferred-in execution of client-defined methods, process development, GMP manufacturing, and regulatory support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Biomedica company profile →
Lanthiopharma
HQ: The Netherlands
Website
- Description: Provider of drug discovery focused on therapeutic lantipeptide drugs for serious diseases, applying proprietary lanthionine-peptide technology (LanthioPepTM) to generate novel peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lanthiopharma company profile →
Mavu Pharma
HQ: United States
Website
- Description: Provider of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mavu Pharma company profile →
Altor BioScience
HQ: United States
Website
- Description: Provider of immunotherapeutic agents for cancer, viral infections, and autoimmune diseases, including ANKTIVA (N‑803), an IL‑15 receptor agonist for non‑muscle invasive bladder cancer; investigational cancer and viral therapies and vaccines (personalized neoepitope-based, HIV, HPV); Tri‑Ad5 vaccine for Lynch syndrome; STAR Fusion reagents for diagnosis/targeting, STAR Multimer reagents for research; and clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altor BioScience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ViroPharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ViroPharma
2.2 - Growth funds investing in similar companies to ViroPharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ViroPharma
4.2 - Public trading comparable groups for ViroPharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →